A Week to Honor Veterans and Save Lives
(Mitch Jelniker)
- Veterans face higher lung cancer risk from military exposures. Early screening and clinical trials save lives. Honor their service this month.
America’s heroes risked everything to protect our freedom, yet many remain unprotected from one of the deadliest threats they face at home: lung cancer. A simple, painless scan, a low-dose CT, can detect lung cancer early, when it’s most treatable. But despite its proven power to save lives, far too few Veterans are getting screened.
For those who served, this gap isn’t just a statistic; it’s deeply personal. Military service can mean exposure to asbestos, burn pits, radon, and other toxic substances that dramatically increase lung cancer risk. The Department of Veterans Affairs has committed to identifying and screening Veterans at risk, yet thousands still go without this potentially lifesaving test.
Let's ensure that “thank you for your service” also means protecting their health.
Early Detection Saved Her LifeAir Force and Navy Veteran Donnita Butler knows firsthand the critical importance of early detection. A routine low-dose CT scan caught her cancer early, and she credits screening with saving her life.
“It’s a simple test that gave me more time,” says Butler. “I tell every Veteran I meet: if you qualify, get screened. It can save your life, too.”
Now, Butler is helping to lead a new mission to inspire others to participate in cutting-edge blood-based research that could revolutionize cancer detection.
The Next Frontier: Blood Tests for CancerScientists are developing simple blood tests that may one day identify lung cancer and other cancers through a single vial of blood.
These next-generation tests rely on biomarkers, which are molecular “fingerprints” from tumor cells circulating in the blood, that can also guide personalized treatments, including targeted therapies and immunotherapies that are more effective and less toxic than traditional chemotherapy.
Veterans are once again at the forefront, volunteering for clinical trials that are accelerating this research.
“Our Veterans are heroes in more ways than one,” says Dr. Drew Moghanaki, Chief of Thoracic Oncology at UCLA Health’s Department of Radiation Oncology. “By participating in studies and screenings, they’re not only protecting their own health but helping advance science for everyone.”
A Partnership for ProgressDr. Moghanaki and Donnita Butler are partnering with Lung Cancer Foundation of America (LCFA) through its Breath of Honor program, an initiative dedicated to increasing lung cancer screening among Veterans and raising awareness of clinical research opportunities. Together, they’re spreading the message that early action can mean the difference between life and loss.
“Tomorrow’s treatments are available today through screening and clinical trials,” says Dr. Moghanaki. “Veterans deserve access to both.”
Learn MoreLearn more to find out if you qualify for lung cancer screening, explore clinical trial opportunities, or learn more about LCFA's Breath of Honor program, visit LCFAmerica.org.
About LCFA
LCFA is dedicated to dramatically improving survival rates and quality of life for people diagnosed with lung cancer. Through funding innovative research, amplifying patient stories, and raising awareness, LCFA brings hope to the millions impacted by the world’s deadliest cancer. Learn more at lcfamerica.org.
- As the holiday lights go up and the to-do lists grow, parents everywhere are navigating a season that should feel joyful, but all too often doesn’t. According to
- Small cell lung cancer (SCLC) is among the most aggressive, deadliest forms of lung cancer, yet it’s still too often overlooked. For decades, treatment options were limited, offering little hope to those diagnosed with SCLC, until now.
Because of research, treatments like the recently FDA-approved Tarlatamab belong to a class of drugs called bispecific T-cell engagers (BiTEs), which harness the immune system to combat cancer. Another treatment, Lurbinectedin, slows or stops the growth of cancer cells in your body. There are also next-generation approaches, such as CAR T-cell therapy and antibody-drug conjugates, and many others, now in clinical trials. Clinical trials, once a last resort, are rapidly becoming a front door to tomorrow’s breakthroughs.
- Do you ever notice a flutter in your chest? Feel unusually tired even after a good night’s sleep? Get winded from walking up the stairs when that never used to happen? These little signs might not feel like a big deal, but they could point to something more serious: atrial fibrillation, or AFib.
- The cancer treatment landscape is undergoing a profound shift. Patients, healthcare providers and advocates are seeking alternatives that deliver both clinical efficacy and quality of life. At the forefront of this movement is GentleCure™, a proven, noninvasive treatment for the most common type of cancer, nonmelanoma skin cancer.
- We all want to look as vibrant as we feel, but sometimes our skin tells a different story. If you've ever felt that dreaded dryness, dullness, or loss of firmness—especially as we get older and lines and wrinkles begin to show—you're not alone. By our forties, cell turnover slows by up to 50%1, weakening skin’s ability to produce natural Hyaluronic Acid. And it makes an impact—more than two-thirds of women over 40 report uncomfortably dry skin, with over 70% saying it's their top concern2.
- From hospitals to surgical centers, med spas to even your dentist’s office—chances are, you or someone in your family has already received medication from a compounding pharmacy without even knowing it.
- By Matt Werbach for the National Psoriasis Foundation 

- For most Americans, the letters "NTM" don’t mean anything. But for tens of thousands of people across the country, they represent something serious: a chronic lung disease that’s often overlooked, misunderstood, and on the rise.
- For many, breathing is something we take for granted, 23,040 breaths a day without a second thought. But for those impacted by lung cancer, every breath matters.